Posted inBiotechnology
AI Chatbots Use Precise Prompts to Accurately Analyze Big Data
In a groundbreaking exploration of artificial intelligence’s potential to accelerate and enhance the analysis of complex health data, a team…
Posted inGenetics
Turning Microalgae-Derived Extracellular Vesicles Into a Next-Generation Drug Delivery Platform
Paris-based AGS Therapeutics (AGS), which is focused on turning microalgae-derived extracellular vesicles (MEVs) into a next-generation drug delivery platform, signed…
Posted inBiotechnology
Korsana crosses into crowded Alzheimer’s field with $175M and anti-amyloid antibody
A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences…
Posted inResearch
Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
Preclinical CRO RoukenBio has inked a partnership with Connecticut-based biologics discovery specialist AVS Bio that aims to leverage each others'…
Posted inGenetics
Prima Mente Unlocks Early-Stage Alzheimer’s Diagnostics with Epigenome Model
AI biology company, Prima Mente, is on a mission to tackle one of the greatest challenges in medicine, uncovering the…
Posted inBiotechnology
Boehringer axes inhaled gene therapy after viewing cystic fibrosis data
Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial.…
Posted inBiotechnology
Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo stock exchange next…
Posted inBiotechnology
Cyrano noses toward pivotal trial after midphase smell loss win
Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to…
Posted inBiotechnology
Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price…
Posted inBiotechnology
Sanofi points to ‘key opportunity’ for Teva-partnered IBD in long-term data
As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term phase…